Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes
Gail Hayward, et al. (2024)
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial
Susanna Naggie, et al. (2022)
Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial
Susanna Naggie, et al. (2023)
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19
Carolyn T. Bramante, et al. (2022)
Effect of Early Treatment with Ivermectin among Patients with Covid-19
Gilmar Reis, et al. (2022)
Errors in Results From Erroneous Exclusion of Participants in Analysis
JAMA (2024)
Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies
Christian Röver, Guido Knapp, Tim Friede (2015)
Compared with, not cited as support
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial
Julio Vallejos, et al. (2021)
Compared with, not cited as support
Ivermectin for preventing and treating COVID-19
Maria Popp, et al. (2022)
Claim on the ledger · Compared with, not cited as support
Conditional on the frozen public aggregate trial tables and stated exploratory log-risk estimators, three 28-day ivermectin hospital-or-death contrasts with 6,984 analysis records yield a random-effects risk ratio of 1.167 (95% modified Hartung-Knapp confidence interval 0.418 to 3.261), all 550 extensions using TOGETHER hospital/death unions compatible with its published margins also include no difference (pooled point estimates 0.947 to 1.079), and replacing concurrent eligible PRINCIPLE controls with all controls changes its crude risk ratio from 1.054 to 0.356, without establishing equivalence or a universal treatment effect.